Sachs Associates’ Post

🚨𝐁𝐑𝐄𝐀𝐊𝐈𝐍𝐆: 𝐀𝐛𝐛𝐕𝐢𝐞 𝐀𝐜𝐪𝐮𝐢𝐫𝐞𝐬 𝐀𝐥𝐢𝐚𝐝𝐚 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐢𝐧 $𝟏.𝟒 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐃𝐞𝐚𝐥 𝐭𝐨 𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 AbbVie has announced its acquisition of Aliada Therapeutics, a privately held biotech specializing in early-stage drugs for Alzheimer’s disease. This $1.4 billion acquisition highlights AbbVie’s strategic expansion into neuroscience, underscoring the importance of Aliada’s proprietary technology that enhances blood-brain barrier penetration—a critical challenge in neurodegenerative drug development. Aliada’s approach to crossing the blood-brain barrier could be transformative for Alzheimer’s treatments, potentially improving drug delivery directly to the brain. AbbVie’s investment in this innovative technology marks a significant bet on the future of Alzheimer’s therapy, a field with vast unmet needs and considerable commercial potential. This acquisition aligns with a larger trend of major players targeting novel mechanisms in the Alzheimer’s and neuroscience space. As the industry watches AbbVie’s latest move, it reaffirms the company’s commitment to addressing neurodegenerative diseases and advancing therapeutic frontiers. #Biotech #AbbVie #AliadaTherapeutics #Alzheimers #Neuroscience #BloodBrainBarrier #Pharma

🌐 🧠 Neuroscience News 🧠 🌐 💷 LoQus23 Therapeutics Ltd announces £35m Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington's disease. "This financing will enable us to develop key clinical data to support the development of our exciting lead programme." David Reynolds - CEO ✅ US approves Karuna Therapeutics / Bristol Myers Squibb schizophrenia drug #Cobenfy with new mode of action. Congratulations to Daphne Zohar Bill Meury Steven Paul Steve Brannan and all those involved. 🤝 AstronauTx appoint Jane Rhodes as their CEO. "Jane has a strong track record of company formation, successful equity financing and forging large enabling Pharma partnerships, all of which will be invaluable in our next phase of growth." Tim Edwards - Chair 💶 BrainEver are looking to raise an additional €5m as part of a larger €35m Series B to launch clinical trials in 2025 to fight Charcot disease. Bernard GIlly ⏩ Ionis Pharmaceuticals, Inc. Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease. "With no approved treatments available for people living with AxD, receiving this Fast Track designation for zilganersen reflects the seriousness of this ultra-rare disease and the significant unmet need for treatment in this patient population" Eugene Schneider, Chief Clinical Development Officer #CNS #Neuroscience #Neurology

𝐋𝐨𝐧𝐳𝐚 𝐚𝐧𝐝 𝐍𝐞𝐮𝐫𝐨𝐒𝐞𝐧𝐬𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐞 𝐭𝐨 𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐀𝐋𝐒 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 Lonza (SIX: LONN) Lonza and NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) NeuroSense Therapeutics announced a collaboration to evaluate biological changes in neurodegenerative diseases, including ALS. This partnership grants NeuroSense access to Lonza's extracellular vesicles expertise. Lonza will develop a method for measuring biomarkers from NDEs to integrate into NeuroSense's lead ALS product, PrimeC. Davide Zocco Davide Zocco, Lonza's Head of Exosomes Development, stated: "Lonza's 'Dev-on-Demand' solution provides NeuroSense with access to expert scientists for their development activities." Alon Ben-Noon Alon Ben-Noon 🇮🇱, NeuroSense's CEO, commented: "This collaboration could be a game-changer for ALS and neurodegeneration. Findings in biomarkers may advance diagnosis and treatment." NeuroSense recently reported positive Phase 2b PARADIGM trial results for PrimeC in ALS, showing a statistically significant slowing of disease progression. #NeurodegenerativeDiseases #ALSResearch #Collaboration #Biotech #Innovation #Biomarkers #Exosomes #Therapeutics #MedicalResearch #Healthcare #Neurology #ClinicalTrials #DrugDevelopment #Lonza #NeuroSense #PrimeC

✨ Every Friday, our Daily Digest delivers essential insights shaping the future of #neuroscience treatment breakthroughs. Dive into the latest developments you need to know. 🔺Takeda Reveals Late-Stage Pipeline with $20B Revenue Potential: The company introduces six therapies targeting unmet medical needs, with Phase 3 data expected in 2025. Key programs like Oveporexton and Zasocitinib highlight Takeda’s commitment to innovation and growth in narcolepsy and psoriasis. 🔺GSK and Muna Therapeutics Join Forces for Alzheimer’s Drug Development: The partnership aims to identify new drug targets using Muna's MiND-MAP platform, with GSK investing €33.5 million upfront and up to €140 million in milestone payments per target. 🔺UCB highlights its collaboration with healthcare providers, advocacy groups, and policymakers to tackle unmet medical needs in epilepsy and rare syndromes, enhancing research and treatment. The company participates in educational events like the AES Annual Meeting to connect experts and advocate for better care. 🔺Beacon Biosignals presented new findings on sleep disturbances in caregivers and children with Lennox-Gastaut Syndrome (LGS) at the AES Annual Meeting. Utilizing the FDA-cleared Dreem 3S™ EEG headband, the studies showed its effectiveness in capturing high-quality sleep data at home. These insights are vital for understanding sleep-related challenges in LGS. 🔺AbbVie has completed its $1.4 billion acquisition of Aliada Therapeutics, enhancing its neuroscience pipeline with ALIA-1758, a Phase 1 Alzheimer's treatment. This acquisition includes a novel blood-brain barrier technology to improve drug delivery. AbbVie aims to address significant unmet needs in Alzheimer's and other CNS disorders through this strategic move. ----- 💡 Sign up for our Daily Digest to stay updated on the pharma and biotech advancements shaping tomorrow’s healthcare breakthroughs. Don’t miss the insights that could impact your next strategic move! #PharmaDailyDigest #Pharmaceuticals #Biotech #CompetitiveIntelligence #AtacanaGroup #neuro  #neuroscience #Alzheimer’s #GSK #AlzeCure #Takeda #UCB #AbbVie

🎉 Exciting News from AbbVie! 🎉 AbbVie has successfully completed its acquisition of Aliada Therapeutics, marking a significant milestone in advancing treatments for Alzheimer’s disease and bolstering its neuroscience R&D capabilities. 💡 What’s New? ALIA-1758: A promising disease-modifying antibody currently in Phase 1 trials for Alzheimer's. Innovative Technology: Aliada's blood-brain barrier (BBB)-crossing platform, enhancing CNS drug delivery. 🧠 Why It Matters Alzheimer’s disease continues to challenge global healthcare systems, impacting millions worldwide. With Aliada's expertise and innovative platforms, AbbVie is taking a major step toward addressing this growing public health concern. ✨ Quote from AbbVie Leadership "With the acquisition now complete, we look forward to advancing potentially disease-modifying therapies and leveraging Aliada's novel CNS drug delivery platform." – Dawn Carlson, M.D., M.P.H., VP, Neuroscience Development This acquisition underscores AbbVie's commitment to tackling complex neurological diseases and advancing transformative solutions for patients globally. #PharmaInnovation #BiotechNews #AlzheimersResearch #Neuroscience #HealthcareInnovation #AbbVie #AliadaTherapeutics

🌟 𝐈𝐧𝐌𝐞𝐝'𝐬 𝐈𝐍𝐌-𝟗𝟎𝟏: 𝐀 𝐍𝐞𝐰 𝐇𝐨𝐩𝐞 𝐟𝐨𝐫 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭! 💡 𝗜𝗻 𝗝𝘂𝗹𝘆 𝟮𝟬𝟮𝟰, InMed Pharmaceuticals recently released preclinical data indicating its proprietary, #smallmolecule compound, INM-901, targets multiple #biological pathways associated with #Alzheimer’sdisease. Among the most interesting data from the recent reports, was the ability of its compound to extend the length of #neurites, which may indicate enhanced neuronal functioning in the #brain and the potential to reverse the #damage caused by Alzheimer’s disease. The company was encouraged with these breakthrough preclinical results and will be advancing the development of the INM-901 Alzheimer’s disease program. InMed's preclinical model of Alzheimer's disease, which is well characterised, showed encouraging outcomes in both in vitro and in vivo trials. The study claims that it might encourage neurite growth and extension, or neutogenesis, a crucial aspect of cell-to-cell communication. In in-vivo experiments, INM-901 also revealed decreased neuroinflammation and improved behaviour, memory, and cognitive function. 𝗕𝗿𝗼𝘄𝘀𝗲 𝗮𝘁 𝗼𝘂𝗿 𝗥𝗲𝗹𝗮𝘁𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁 👉:https://bit.ly/46jbV2x #AlzheimersTreatment #InnovativeTherapy #AlzheimersResearch #MultiFactorialApproach #BreakthroughMedicine #NeuroScience #AlzheimersHope #prophecymarketinsights

🧬 in Precision Medicine: Arialys Therapeutics Emerges with $58M to Transform Neuropsychiatric Treatment TL;DR: • Launches with $58M from top investors including J&J • Developing ART5803 for anti-NMDA receptor encephalitis • Plans FDA submission for clinical trials in 2024 • Exploring applications for schizophrenia and Alzheimer's Arialys Therapeutics is pioneering an immune system-focused approach to neuropsychiatric disorders, mirroring successful precision oncology strategies. Their lead candidate, ART5803 (acquired from Astellas Pharma), shows promising preclinical results in treating brain inflammation and behavioral symptoms. Backed by industry giants including Avalon BioVentures, MPM BioImpact, and J&J's venture arm, Arialys joins a resurgent neuroscience field that's seeing renewed interest from major pharma companies. This development follows recent momentum in neuroscience, with Neumora Therapeutics' $600M+ funding and upcoming IPO, plus GSK's renewed commitment to brain disease research. 💡 What are your thoughts on the intersection of immunology and neuropsychiatry? Share your insights on this emerging therapeutic approach. #Biotech #PrecisionMedicine #Neuroscience #BiotechInnovation #DrugDevelopment #intelligencesimplified #pharma #biotech #biodatastudio

Very excited about this collaboration with the PSPP! At Goldenrod Therapeutics, we are developing next-generation, small molecule, oral PDE4B inhibitors for the treatment of severely debilitating diseases that affect the central nervous system and for which current treatments are either inadequate or non-existent. Globally, about 1 in 5 people suffer from chronic pain, an extremely complex and debilitating condition which varies significantly between individuals. Unfortunately, highly addictive opioids are still the most commonly prescribed medications for chronic pain and, despite decades of effort, there are still no exceptional alternatives on the market. Goldenrod's non-opioid small molecule drugs have the potential to change this! Importantly, this partnership marks our second collaboration with an NIH Institutional Program - the first being our acceptance into NIDA's Addiction Treatment Discovery Program (ATDP) in 2022. We are thrilled to work with these key partners, among others, to advance Goldenrod's promising new treatments forward and to address the unmet needs of patients worldwide. #chronicpain #painresearch #paintherapeutics

We are excited to announce that one of our Fannin-founded companies, Goldenrod Therapeutics, has been accepted into the National Institute of Neurological Disorders and Stroke (NINDS) Preclinical Screening Platform for Pain (PSPP). In alignment with the NIH HEAL Initiative, the PSPP is an efficient, rigorous, one-stop screening resource to accelerate discovery of effective, non-addictive, non-opioid pain therapies. The program can assess in vitro and pharmacokinetic profiles, side effect profiles, abuse liability, and efficacy in models relevant to human pain conditions.     Support from the PSPP Program will help accelerate the development of Goldenrod’s small molecule therapeutics towards treating chronic pain, which affects more than 51 million people in the United States alone. We look forward to this partnership and its potential for advancing these promising therapeutics towards the clinic. #Biotech #Neuroscience #Therapeutics #Innovation #Fannin

𝐂₂𝐍 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬 𝐰𝐢𝐭𝐡 𝐌𝐞𝐝𝐢𝐟𝐨𝐫𝐝 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐭𝐨 𝐄𝐱𝐩𝐚𝐧𝐝 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫'𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐢𝐧 𝐉𝐚𝐩𝐚𝐧 C₂N Diagnostics, LLC (“C2N”) C2N Diagnostics announces a partnership with Mediford Corporation, a premier provider of clinical research in Japan, expanding access to C₂N Biopharma Clinical Research Services. This collaboration enhances access to C₂N’s Precivity™ line of blood tests for Alzheimer’s disease (AD) diagnosis and monitoring. The alliance with Mediford Corporation increases access to C₂N’s highly sensitive mass spectrometry-based biomolecule analysis, aiding researchers in Japan. C₂N’s expertise includes the Precivity™ line, offering high-performance blood tests for AD diagnosis, prognosis, staging, and treatment monitoring, including innovative biomarkers like MTBR-tau for detecting neurofibrillary “tau” tangles. Dr. Maki Hoshiko Maki Hoshiko joins C₂N to lead its Japan strategy and scientific collaborations, leveraging her expertise as a neuroscientist and commercialization professional. Japan's high prevalence of Alzheimer's disease underscores the importance of this expansion, with the country accounting for a significant portion of diagnosed cases globally. C₂N’s CEO, Dr. Joel Braunstein Joel Braunstein, MD, emphasizes the strategic significance of the partnership in advancing Alzheimer’s research and treatment solutions. Mediford Corporation President, Mr. Kei Shimizu, highlights C₂N’s reputation for quality and innovation in Alzheimer’s diagnostics, underscoring the value of their blood biomarker testing for clinical trial and treatment monitoring. #AlzheimersAwareness #Neurology #Biopharma #BrainHealth #MedicalInnovation #ClinicalTrials #Diagnostics #JapanHealthcare #Neuroscience #ResearchPartnership #MedTech #Biomarkers #AlzheimersPrevention